COMP <GO>
CANF vs XBIO // ENTERPRISE SCALE & MARKET CAP
Can-Fite Biopharma Ltd each representing two (2) (NYSE) VS. Xenetic Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: CANF 1
— XBIO 4
▲ ENTERPRISE SCALE & MARKET CAP LEADER: CANF
LAST: $1.66 (+0.61%) • MKT CAP: $5.0M
market-cap
$5.0M
LAST: $2.12 (+0.95%) • MKT CAP: $5.0M
market-cap
$5.0M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CANF VS. XBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CANF | XBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -30.30% | -4.70 | XBIO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -39.90% | 19.00% | -58.90 | XBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 4/9 | -2.00 | XBIO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 23.6 | 43.5 | -19.97 | XBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $5.0M | $5.0M | $64.8K | CANF | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CANF REV | XBIO REV | CANF GROSS % | XBIO GROSS % | CANF FCF | XBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $405.0K | $3.0M | — | — | -$9.0M | -$2.3M |
| FY 2024 | $674.0K | $2.5M | — | — | -$7.6M | -$2.8M |
| FY 2023 | $743.0K | $2.5M | — | — | -$8.4M | -$4.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CANF // BETA —
XBIO // BETA —